TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Blood
Authors
Keywords
Abstract

Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or decitabine (DEC). Mutations were examined for association with response and overall survival. The overall response rate of 47% was not different between agents. Clonal TET2 mutations predicted response (odds ratio [OR] 1.99, P = .036) when subclones unlikely to be detected by Sanger sequencing (allele fraction

Year of Publication
2014
Journal
Blood
Volume
124
Issue
17
Pages
2705-12
Date Published
2014 Oct 23
ISSN
1528-0020
URL
DOI
10.1182/blood-2014-06-582809
PubMed ID
25224413
PubMed Central ID
PMC4208285
Links
Grant list
P30 CA016672 / CA / NCI NIH HHS / United States
P01CA108631 / CA / NCI NIH HHS / United States
R01 HL082945 / HL / NHLBI NIH HHS / United States
CA016672 / CA / NCI NIH HHS / United States
P01 CA108631 / CA / NCI NIH HHS / United States
P30 CA023100 / CA / NCI NIH HHS / United States
K08 DK091360 / DK / NIDDK NIH HHS / United States
K08DK091360 / DK / NIDDK NIH HHS / United States
R01HL082945 / HL / NHLBI NIH HHS / United States